デフォルト表紙
市場調査レポート
商品コード
1563980

乳がん検診の世界市場

Breast Cancer Screening


出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
乳がん検診の世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乳がん検診の世界市場は2030年までに83億米ドルに達する

2023年に59億米ドルと推定される乳がん検診の世界市場は、分析期間2023-2030年にCAGR 5.1%で成長し、2030年には83億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるイメージング検査は、CAGR 5.8%を記録し、分析期間終了時には48億米ドルに達すると予測されます。免疫組織化学検査分野の成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 8.0%で成長予測

米国の乳がん検診市場は2023年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0%と4.1%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界の乳がん検診市場- 主要動向と促進要因のまとめ

乳がん検診が早期発見に不可欠な理由とは?

乳がん検診は、世界中で何百万人もの女性が罹患している乳がんの早期発見において極めて重要な役割を果たしています。検診の第一の目的は、症状が明らかになる前であっても、その初期段階でがんを発見することです。乳房組織の異常を検出するために、マンモグラフィ、超音波、MRI、遺伝子検査などの技術が利用されます。その中でもマンモグラフィは、健康診断では感じられないような小さな腫瘍を発見することができるため、現在でも最も広く推奨され、利用されている方法です。定期的な検診は、40歳以上の女性や乳がんの家族歴のある女性にとって特に重要です。早期かつ効果的な治療が可能になることで、乳がんによる死亡リスクを大幅に減らすことができるからです。

テクノロジーは乳がん検診にどのような革命をもたらしたか?

乳がん検診の分野は、技術革新によって大きく進歩し、以前よりも精密で、侵襲性が低く、より身近なものとなりました。主要な発展であるデジタル・マンモグラフィは、画像の鮮明さを向上させ、微細な異常の発見を可能にしました。この技術はまた、画像の保存と共有を容易にし、患者ケアにおいてより協力的で情報に基づいた意思決定を可能にします。さらに、3Dマンモグラフィ(トモシンセシス)は、乳房組織の多次元的なビューを提供することで、偽陽性を減らし、診断の精度を向上させる画期的な技術として登場しました。人工知能(AI)を検診プロセスに取り入れることも変革的な飛躍であり、AIツールは現在、放射線科医を支援し、他の方法では見落とされるかもしれないがんの微妙な兆候を特定することができます。これらの技術的進歩は、乳がん検診の精度を高めるだけでなく、プロセスをより効率的にし、それによって患者の転帰を改善しています。

乳がん検診の将来を形作る新しい動向とは?

乳がん検診を取り巻く環境は急速に進化しており、いくつかの新しい動向がこの重要なヘルスケアサービスの将来の舞台となっています。顕著な動向は、遺伝、年齢、乳房密度などの個々の危険因子を考慮して検診プロトコルを調整する、個別化検診アプローチへの移行です。この個別化されたアプローチは、過剰診断や不必要な治療に関連するリスクを減らしながら、検診の効果を最大化しようとするものです。もう一つの新たな動向は、造影マンモグラフィや乳房MRIのような高度な画像技術の使用が増加していることです。また、AIをスクリーニング検査に統合する動きも活発化しており、放射線科医に診断精度と効率を向上させる高度なツールを提供しています。さらに、十分なサービスを受けていない地域での検診サービスへのアクセスを拡大し、地理的・経済的環境にかかわらず、すべての女性が早期発見の恩恵を受ける機会を得られるようにすることに注目が集まっています。このような動向は、この分野における大きな技術革新を促し、乳がん検診が多様な人々のニーズに適応し、進歩し続けることを確実にしています。

乳がん検診市場の成長を促進している要因は?

乳がん検診市場の成長は、技術的進歩、進化するヘルスケアプラクティス、意識の高まりの組み合わせによって促進されています。主な促進要因の1つは、3Dマンモグラフィの普及や画像処理におけるAIの統合など、検診技術における継続的な技術革新であり、これによりがん検出の精度と信頼性が向上しています。また、早期発見が生存率の向上に不可欠であることから、特に高齢化社会における乳がん罹患率の上昇も検診サービスの需要増に寄与しています。さらに、個別化医療の動向により、遺伝子検査やその他のリスク評価ツールの市場が拡大しています。公衆衛生への取り組みや意識向上キャンペーンは、特に確立されたヘルスケアシステムがこれらのサービスへの容易なアクセスを提供している地域において、定期的なスクリーニングへの参加率を大幅に押し上げています。これらの要因が総合的に乳がん検診市場の堅調な拡大を支えており、技術の進歩や世界人口のニーズの変化に応じて進化し続けています。

調査対象企業の例(全42件)

  • A&G Pharmaceutical, Inc.
  • Agendia NV
  • Biocrates Life Sciences AG
  • Hologic, Inc.
  • Metabolomic Technologies Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10793

Global Breast Cancer Screening Market to Reach US$8.3 Billion by 2030

The global market for Breast Cancer Screening estimated at US$5.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Immunohistochemistry Test segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.0% CAGR

The Breast Cancer Screening market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Breast Cancer Screening Market - Key Trends and Drivers Summarized

Why Is Breast Cancer Screening Crucial for Early Detection?

Breast cancer screening plays a pivotal role in the early detection of breast cancer, a prevalent disease that affects millions of women worldwide. The primary goal of screening is to identify cancer in its earliest stages, even before symptoms become apparent, thus allowing for timely and potentially life-saving treatments. Techniques such as mammography, ultrasound, MRI, and genetic testing are utilized to detect abnormalities in breast tissue. Among these, mammography remains the most widely recommended and utilized method due to its ability to detect small tumors that might not be felt during a physical examination. Regular screening is especially important for women over 40 or those with a family history of breast cancer, as it can significantly reduce the risk of death from the disease by enabling earlier and more effective treatment.

How Has Technology Revolutionized Breast Cancer Screening?

The field of breast cancer screening has been significantly advanced by technological innovations, making the process more precise, less invasive, and more accessible than ever before. Digital mammography, a key development, has improved the clarity of images and allowed for better detection of minute abnormalities. This technology also facilitates easier storage and sharing of images, enabling more collaborative and informed decision-making in patient care. Furthermore, 3D mammography, or tomosynthesis, has emerged as a game-changer by providing a multi-dimensional view of breast tissue, which reduces false positives and improves the accuracy of diagnoses. The incorporation of artificial intelligence (AI) into the screening process is another transformative leap, with AI tools now capable of assisting radiologists in identifying subtle signs of cancer that might otherwise be overlooked. These technological advancements are not only enhancing the accuracy of breast cancer screening but are also making the process more efficient, thereby improving outcomes for patients.

What New Trends Are Shaping the Future of Breast Cancer Screening?

The landscape of breast cancer screening is rapidly evolving, with several new trends setting the stage for the future of this critical healthcare service. A prominent trend is the move towards personalized screening approaches, where individual risk factors such as genetics, age, and breast density are taken into account to tailor screening protocols. This personalized approach seeks to maximize the effectiveness of screening while reducing the risks associated with overdiagnosis and unnecessary treatments. Another emerging trend is the increasing use of advanced imaging technologies like contrast-enhanced mammography and breast MRI, which offer more detailed visualization and are particularly beneficial for individuals at higher risk. The integration of AI into screening procedures is also gaining traction, providing radiologists with advanced tools to improve diagnostic accuracy and efficiency. Additionally, there is a growing focus on expanding access to screening services in underserved communities, ensuring that all women have the opportunity to benefit from early detection, regardless of their geographic or economic circumstances. These trends are driving significant innovation in the field, ensuring that breast cancer screening continues to advance and adapt to the needs of diverse populations.

What Factors Are Fueling Growth in the Breast Cancer Screening Market?

The growth in the breast cancer screening market is fueled by a combination of technological advancements, evolving healthcare practices, and increasing awareness. One of the key drivers is the ongoing innovation in screening technologies, such as the widespread adoption of 3D mammography and the integration of AI in imaging, which are improving the accuracy and reliability of cancer detection. The rising incidence of breast cancer, especially among aging populations, is also contributing to the increased demand for screening services, as early detection is critical for improving survival rates. Furthermore, the trend towards personalized medicine is expanding the market for genetic testing and other risk assessment tools, as more screening programs are tailored to individual risk profiles. Public health initiatives and awareness campaigns have significantly boosted participation rates in regular screening, particularly in regions where established healthcare systems provide easy access to these services. These factors are collectively supporting the robust expansion of the breast cancer screening market, as it continues to evolve in response to technological advancements and the changing needs of the global population.

Select Competitors (Total 42 Featured) -

  • A&G Pharmaceutical, Inc.
  • Agendia NV
  • Biocrates Life Sciences AG
  • Hologic, Inc.
  • Metabolomic Technologies Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Breast Cancer Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Breast Cancer Propels Demand for Advanced Screening Methods
    • Increased Awareness and Early Detection Efforts Expand Addressable Market Opportunity
    • Advancements in Imaging Techniques Strengthen the Business Case for Enhanced Screening Tools
    • Growing Adoption of 3D Mammography Spurs Growth in Breast Cancer Screening
    • Rising Demand for Non-Invasive Screening Options Generates Need for Advanced Diagnostic Methods
    • Expansion of National Screening Programs Sustains Growth in the Breast Cancer Screening Market
    • Advances in Genetic Testing Propel Innovation in Risk-Based Screening Strategies
    • Rising Demand for Portable and Accessible Screening Devices Expands Market for Mobile Screening Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Imaging Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Genetic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Blood Marker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • JAPAN
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • CHINA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • EUROPE
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • FRANCE
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • GERMANY
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • INDIA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030
  • AFRICA
    • Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030

IV. COMPETITION